Clinical trial
Phase I Safety Study of Anti-HIV Immune Serum Globulin (Human)
NCT00002036 · Abbott, Industry · Completed
Key facts
| NCT number | NCT00002036 |
|---|---|
| Title | Phase I Safety Study of Anti-HIV Immune Serum Globulin (Human) |
| Official title | Phase I Safety Study of Anti-HIV Immune Serum Globulin (Human) |
| Lead sponsor | Abbott, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Anti-HIV Immune Serum Globulin (Human) |
| Enrollment | 12 |
| First posted | Aug 31, 2001 |
| Last update posted | Feb 20, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: